Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma.

Strahlenther Onkol · 2023 · PMC10361861 · PMID 36862155

Europe PMC DOI

hedged sentence

0.0920

closest p · 1.8× alpha

0.0920

boldest claim

The sentences

a nonsignificant trendP = 0.092so close (0.05 < p ≤ 0.1)

Dose escalation to > 63 Gy (maximum 66.6 Gy) to the primary tumor in 38/87 patients revealed a nonsignificant trend for improved 3‐year CFS (82.4% vs. 97%, P = 0.092), a significantly improved CFS for T2/T3 tumors (72.6% vs. 100%, P = 0.008), and a significantly improved 3‐year PFS for T1/T2 tumors (76.7% vs. 100%, P = 0.035).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.